Treatment of Cladosporium Skin Infections
Oral itraconazole is the recommended first-line treatment for Cladosporium skin infections (phaeohyphomycosis), typically at 200-400 mg daily for 2-6 months, with treatment continuing 2-4 weeks after complete lesion resolution.
Diagnostic Confirmation First
Before initiating treatment, confirm the diagnosis through:
- Fungal culture of tissue or aspirate samples (gold standard)
- Histopathology showing pigmented septate hyphae and brown fungal elements
- KOH preparation demonstrating dark pigmented yeast forms and brown septate hyphae
- DNA sequencing if available for species-level identification 1, 2
Primary Treatment Approach
Itraconazole (First-Line)
The evidence consistently supports itraconazole as the most effective agent:
- Standard dosing: 200 mg daily 2
- Refractory cases: Escalate to 400 mg daily 3 or even 600 mg daily for severe/progressive disease 4
- Duration: Minimum 2 months, typically 2-6 months depending on response 1, 2
- Continue treatment: 2-4 weeks beyond complete clinical resolution to prevent relapse
The case series demonstrate response rates are high when adequate doses and duration are used. One patient with C. cladosporioides achieved complete resolution with 200 mg daily for 2 months 2, while another required 600 mg daily for 6 months after failing lower doses 4.
Alternative Agents
Terbinafine can be considered but has mixed results:
- One case showed initial response but relapsed after 9 months of therapy 4
- Less reliable than itraconazole based on available evidence
Potassium iodide (SSKI) is an older, cost-effective option:
- Successfully used for C. oxysporum cutaneous infection 5
- Consider when itraconazole is unavailable or unaffordable
- Expect significant side effects (dysgeusia, GI intolerance, acneiform eruptions)
Refractory Disease Management
When standard itraconazole fails after 6-9 months 3:
- Verify compliance and adequate drug levels if possible
- Increase itraconazole dose to 400-600 mg daily 3, 4
- Add adjunctive therapy: Aminolevulinic acid photodynamic therapy (ALA-PDT) has shown success as combination treatment, particularly for facial/periorbital lesions unsuitable for surgery 3
- Surgical excision should be considered for localized lesions when feasible
Critical Pitfalls to Avoid
- Premature discontinuation: Stopping treatment at clinical improvement rather than continuing 2-4 weeks beyond complete resolution leads to relapse 4
- Inadequate dosing: Starting with subtherapeutic doses (e.g., 100 mg daily) may lead to treatment failure
- Misdiagnosis: Cladosporium infections can mimic acne, warts, or trichotillomania 1, 2—always confirm with culture
- Amphotericin B is ineffective: One case showed no response to amphotericin B and flucytosine 4—avoid this agent
Special Considerations
Location-specific challenges: Periorbital or facial lesions may not be amenable to surgical debridement, making medical therapy and adjunctive ALA-PDT particularly important 3.
Immunocompromised patients: While not extensively discussed in the Cladosporium literature, higher doses and longer durations are likely needed, extrapolating from general phaeohyphomycosis management principles.